Abstract

PurposeThe survival duration of elderly patients with epithelial ovarian carcinoma is shorter than that of their younger counterparts. This variation in survival duration is likely attributed to differences in the distribution of histological type or grade, International Federation of Gynecology and Obstetrics (FIGO) staging, and undertreatment, but this observation remains controversial. This study aimed to investigate the biological factors other than selection bias associated with the decreased survival of elderly patients with ovarian carcinoma.MethodsA total of 314 serous ovarian cancer (SOC) patients from Jiangsu Institute of Cancer Research (JICR, PRC) between 2002 and 2012 were retrospectively analyzed, and 774 cases from MD Anderson Cancer Center (MDACC, USA) between 1992 and 2012 were used for validation. The 8-hydroxy-2′-deoxyguanine (8-OHdG) concentration in leukocyte DNA was evaluated by using commercially available enzyme-linked immunosorbent assay kits, and tissue expression was assayed through immunohistochemistry. The associations between survival durations and covariates were assessed by using a Cox proportional hazards model and by conducting a log-rank test.ResultsAdvanced age ≥ 65 years was correlated with high histological grade (p = 0.02), performance status (p = 0.03), primary treatment (p = 0.00), and suboptimal surgery outcome (p = 0.04) in SOC patients from JICR. Age, FIGO stage, histological grade, and optimal surgery were independently associated with the progression-free survival (PFS; p = 0.03, p = 0.03, p = 0.02, and p = 0.04, respectively) and overall survival (OS; p = 0.02, p = 0.04, p = 0.02, and p = 0.02, respectively) of the SOC patients from JICR. The 8-OHdG concentration in the leukocyte DNA was higher in the elderly patients than in the younger cases. The high 8-OHdG concentration in the leukocyte DNA indicated poorer median OS (30.0 months, confidence interval [CI]: 23.5–36.5 vs. 42.8 months, [CI] 38.3–47.2) and PFS (14.6 months, [CI] 11.9–17.2 vs. 18.9 months, [CI] 14.4–23.4) than those of their corresponding counterparts in the SOC patients who achieved a clinical complete response from primary treatment.ConclusionsCompared with younger cases, elderly patients with SOC were commonly characterized by high tumor grade, poor performance status, and undertreatment. High 8-OHdG concentration in leukocyte DNA was associated with advanced age and poor prognosis in SOC patients.

Highlights

  • Epithelial ovarian cancer (EOC) is the leading lethal gynecological malignancy affecting women worldwide [1,2,3]

  • The number of Neoadjuvant chemotherapy (NAC), the opportunity of interval cytoreduction surgery (IDS), and adjuvant chemotherapy cycles were administered on the basis of the decision of the multidisciplinary team (MDT)

  • We further found that the 8-OHdG expression in serous ovarian cancer (SOC) tumor was higher in the elderly patients than in the younger cases, but the difference was not significant

Read more

Summary

Introduction

Epithelial ovarian cancer (EOC) is the leading lethal gynecological malignancy affecting women worldwide [1,2,3]. EOC is generally considered an age-related disease. Deng et al Journal of Ovarian Research (2017) 10:36 age-oriented biological factors related to the prognosis of EOC should be investigated [10, 11]. The standard care for patients with EOC involves cytoreductive surgery, which is known as optimal debulking, and six to eight cycles of frontline chemotherapy, including platinum compound with taxane. The survival of patients with EOC has generally improved for the past three decades, this progress has yet to provide benefits for elderly patients. Compared with young age, advanced age has been reported as an adverse prognostic factor influencing EOC. Contradicting results have been obtained, and the mechanisms underlying this observation are poorly defined [12,13,14,15]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call